Aclarion ACON 深 滬
已收盤 08-07 16:00:00 美东时间
2.29
-0.060
-2.55%
華盛通- 最 高2.36
- 今 開2.32
- 成交量 5.82万股
- 最 低 2.23
- 昨 收 2.35
- 總市值 563.86万
- 52周最高 12.03
- 市盈率 靜 --
- 換手率 2.36%
- 52周最低 1.95
- 委 比 -8.68%
- 總股本 246.23万
- 歷史最高 586116.00
- 量 比 1.36
- 振 幅 5.53%
- 歷史最低 1.95
- 每 手 1
- 風險率 2.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026
Aclarion, Inc. reported strong momentum in the first half of 2026, with a 141% year-over-year scan volume growth and 71% sequential growth, driven by increased physician engagement and commercial execution. The company expanded Nociscan utilization in the U.S. and U.K., secured reimbursement in the U.K., and partnered with PRIA Healthcare to establish payer coverage in the U.S. Progress continued toward the CLARITY trial readout, and intellectual...
07-29 11:00
Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real-World Clinical Practice
Aclarion, Inc. presented two abstracts at the ASPN Annual Meeting highlighting Nociscan's clinical utility in chronic low back pain management. The first abstract demonstrated the successful integration of MRS technology into clinical workflows for identifying symptomatic discs, while the second presented a case study where Nociscan guided basivertebral nerve ablation in a patient without classic Modic changes, achieving 95% pain relief. Nociscan...
07-21 11:00
Aclarion Announces Texas Spine Care Center As New Clinical Site In Chronic Low bAck pain Randomized Independent Trial studY Trial
Texas Spine Care Center is a high-volume orthopedic spine practice with a philosophy of understanding the exact source of a patient's pain before recommending treatment CLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chr...
07-07 19:06
Aclarion Announces Texas Spine Care Center as New CLARITY Site
Texas Spine Care Center has joined the CLARITY trial, a clinical study aiming to demonstrate the effectiveness of Nociscan in improving surgical outcomes for chronic low back pain. Nociscan uses MR Spectroscopy and AI to identify pain sources, offering objective biomarker insights. The trial, led by Aclarion, Inc., involves multiple high-volume sites and evaluates Nociscan's impact on pain reduction over 12 months. With a focus on precise, indivi...
07-07 11:00
Aclarion Launches Market Access Program In Partnership With PRIA Healthcare
Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven platform for chronic low back pain.Program aims to follow successful reimbursement wins in the UK that are translating
06-09 19:04
Aclarion Board Reviews Echo Lake's Unsolicited Public Proposal And Unanimously Determined To Reject It
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help
06-08 19:13
美股大行评级 | Susquehanna上调美光目标价从600美元升至1750美元；戴尔、MongoDB、网泰信息存储、Nextpower、Okta等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从7美元升至7.5美元；Susquehanna：维持美光科技"积极"评级，目标价从600美元升至1750美元
06-01 14:11
Echo Lake Capital Offers To Acquire Aclarion At $4.00/Share And Contingent Value Right Representing Right For Stockholders To Receive 80% Of Net Proceeds From Nociscan Sale.
Offers $4.00 per share in cash plus CVRStock currently trades below the value of its cash and other assetsBelieves company's public shell worth at least another $6 million if Board effected a reverse takeoverStock price
05-28 20:04
Aclarion Q1 EPS $(1.34) Beats $(1.55) Estimate, Sales $21.140K Miss $25.000K Estimate
Aclarion (NASDAQ:ACON) reported quarterly losses of $(1.34) per share which beat the analyst consensus estimate of $(1.55) by 13.55 percent. This is a 85.62 percent increase over losses of $(9.32) per share from the same
05-14 05:50
Aclarion Establishes Second Commercial Agreement With Weill Cornell Medicine; Deal Brings Nociscan To Weill Cornell Medicine And Och Spine At Newyork-Presbyterian/Weill Cornell Medical Center
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through
05-05 18:11
